Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
In order to decode the roles that N-methyl-D-aspartate (NMDA) receptors play in excitatory neurotransmission, synaptic plasticity, and neuropathologies, there is need for ligands that differ in their subtype selectivity. The conantokin family of Conus peptides is the only group of peptidic natural products known to target NMDA receptors. Using a search that was guided by phylogeny, we identified new conantokins from the marine snail Conus bocki that complement the current repertoire of NMDA receptor pharmacology. Channel currents measured in Xenopus oocytes demonstrate conantokins conBk-A, conBk-B, and conBk-C have highest potencies for NR2D containing receptors, in contrast to previously characterized conantokins that preferentially block NR2B containing NMDA receptors. Conantokins are rich in γ-carboxyglutamate, typically 17-34 residues, and adopt helical structure in a calcium-dependent manner. As judged by CD spectroscopy, conBk-C adopts significant helical structure in a calcium ion-dependent manner, while calcium, on its own, appears insufficient to stabilize helical conformations of conBk-A or conBk-B. Molecular dynamics simulations help explain the differences in calcium-stabilized structures. Two-dimensional NMR spectroscopy shows that the 9-residue conBk-B is relatively unstructured but forms a helix in the presence of TFE and calcium ions that is similar to other conantokin structures. These newly discovered conantokins hold promise that further exploration of small peptidic antagonists will lead to a set of pharmacological tools that can be used to characterize the role of NMDA receptors in nervous system function and disease.
Acklin,
5-Aminomethylquinoxaline-2,3-diones, Part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists.
1998, Pubmed
Acklin,
5-Aminomethylquinoxaline-2,3-diones, Part III: Arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists.
1998,
Pubmed Ametamey,
Synthesis, radiolabelling and biological characterization of (D)-7-iodo-N-(1-phosphonoethyl)-5-aminomethylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptors.
2000,
Pubmed Auberson,
N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists.
1999,
Pubmed Auberson,
5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition.
2002,
Pubmed Bashford,
Generalized born models of macromolecular solvation effects.
2000,
Pubmed Blandl,
Binding of cations to individual gamma-carboxyglutamate residues of conantokin-G and conantokin-T.
1999,
Pubmed Blandl,
NMDA-receptor antagonist requirements in conantokin-G.
1998,
Pubmed Blandl,
Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R.
2001,
Pubmed Blandl,
Structure-function relationships of the NMDA receptor antagonist peptide, conantokin-R.
2000,
Pubmed Bulaj,
Integrating the discovery pipeline for novel compounds targeting ion channels.
2008,
Pubmed Case,
The Amber biomolecular simulation programs.
2005,
Pubmed Chandler,
Polyamine-like actions of peptides derived from conantokin-G, an N-methyl-D-aspartate (NMDA) antagonist.
1993,
Pubmed Choi,
Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor.
1999,
Pubmed
,
Xenbase Costa,
N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse.
2009,
Pubmed
,
Xenbase Counihan,
Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons.
1998,
Pubmed Cull-Candy,
NMDA receptor subunits: diversity, development and disease.
2001,
Pubmed Dingledine,
The glutamate receptor ion channels.
1999,
Pubmed Donevan,
Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors.
2000,
Pubmed
,
Xenbase Feng,
Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid.
2004,
Pubmed
,
Xenbase Hammerland,
Conantokin-G selectively inhibits N-methyl-D-aspartate-induced currents in Xenopus oocytes injected with mouse brain mRNA.
1992,
Pubmed
,
Xenbase Hollmann,
Cloned glutamate receptors.
1994,
Pubmed Hummel,
Anatomical localization and expression pattern for the NMDA-2D receptor subunit in a rat model of neuropathic pain.
2008,
Pubmed Jones,
Protein secondary structure prediction based on position-specific scoring matrices.
1999,
Pubmed Kabsch,
Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features.
1983,
Pubmed Karlsson,
Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn - effects of peripheral nerve lesion and inflammation.
2002,
Pubmed Khosravani,
Prion protein attenuates excitotoxicity by inhibiting NMDA receptors.
2008,
Pubmed Kinarsky,
Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket.
2005,
Pubmed
,
Xenbase Klein,
Inhibition of MK801 binding in adult rat brain sections by conantokin-G and conantokin-T.
1999,
Pubmed Kosinski,
Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus.
1998,
Pubmed Layer,
Conantokins: peptide antagonists of NMDA receptors.
2004,
Pubmed Lin,
Role of modified glutamic acid in the helical structure of conantokin-T.
1997,
Pubmed Low,
Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors.
2000,
Pubmed
,
Xenbase Micu,
NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia.
2006,
Pubmed Minami,
Characterization of the glutamatergic system for induction and maintenance of allodynia.
2001,
Pubmed Morley,
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
2005,
Pubmed
,
Xenbase Mosley,
Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists.
2010,
Pubmed
,
Xenbase Mosley,
Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors.
2009,
Pubmed
,
Xenbase Olivera,
Diversity of the neurotoxic Conus peptides: a model for concerted pharmacological discovery.
2007,
Pubmed Olivera,
Conus peptides: biodiversity-based discovery and exogenomics.
2006,
Pubmed Paoletti,
High-affinity zinc inhibition of NMDA NR1-NR2A receptors.
1997,
Pubmed
,
Xenbase Rachline,
The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.
2005,
Pubmed
,
Xenbase Rigby,
Role of gamma-carboxyglutamic acid in the calcium-induced structural transition of conantokin G, a conotoxin from the marine snail Conus geographus.
1997,
Pubmed Schüler,
Formation of NR1/NR2 and NR1/NR3 heterodimers constitutes the initial step in N-methyl-D-aspartate receptor assembly.
2008,
Pubmed
,
Xenbase Schwieters,
Internal coordinates for molecular dynamics and minimization in structure determination and refinement.
2001,
Pubmed Schwieters,
The Xplor-NIH NMR molecular structure determination package.
2003,
Pubmed Sheng,
Specific determinants of conantokins that dictate their selectivity for the NR2B subunit of N-methyl-D-aspartate receptors.
2010,
Pubmed Sheng,
Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides.
2007,
Pubmed Sheng,
The selectivity of conantokin-G for ion channel inhibition of NR2B subunit-containing NMDA receptors is regulated by amino acid residues in the S2 region of NR2B.
2009,
Pubmed Simeone,
Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system.
2004,
Pubmed Skjaerbaek,
Determination of the solution structures of conantokin-G and conantokin-T by CD and NMR spectroscopy.
1997,
Pubmed Teichert,
Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors.
2007,
Pubmed Tsai,
The effects of alanine-substituted conantokin-G and ifenprodil on the human spermine-activated N-methyl-D-aspartate receptor.
2005,
Pubmed Twede,
Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads.
2009,
Pubmed Twede,
Conantokin-Br from Conus brettinghami and selectivity determinants for the NR2D subunit of the NMDA receptor.
2009,
Pubmed
,
Xenbase Warder,
The roles of individual gamma-carboxyglutamate residues in the solution structure and cation-dependent properties of conantokin-T.
1998,
Pubmed Warder,
Amino acid determinants for NMDA receptor inhibition by conantokin-T.
2001,
Pubmed Warder,
The NMR solution structure of the NMDA receptor antagonist, conantokin-T, in the absence of divalent metal ions.
1997,
Pubmed Wilson,
μ-Conotoxins that differentially block sodium channels NaV1.1 through 1.8 identify those responsible for action potentials in sciatic nerve.
2011,
Pubmed
,
Xenbase Wittekindt,
Point mutations identify the glutamate binding pocket of the N-methyl-D-aspartate receptor as major site of conantokin-G inhibition.
2001,
Pubmed
,
Xenbase
